Colorectal Cancer Coverage from Every Angle

Novel Chimeric Monoclonal Antibody Under Study in Metastatic Colorectal Cancer

By: Joshua D. Madera, MS
Posted: Tuesday, August 11, 2020

Treatment with the novel monoclonal antibody ensituximab (NEO-102) exhibited “modest anticancer activity” in patients with advanced, refractory colorectal cancer who express MUC5AC, according to a study published in Clinical Cancer Research. Ensituximab targets a variant of MUC5AC. Muhammad S. Beg, MD, of the University of Texas Southwestern Medical Center, Dallas, and colleagues conducted this phase II study and presented their findings.

A total of 63 patients with advanced, refractory colorectal cancer who express MUC5AC were enrolled in the study. All patients had previously received ineffective standard treatment. Of these patients, 53 received 3 mg/kg intravenously of ensituximab every 2 weeks, as recommended by the multicenter study guidelines. Treatment was continued until disease progression or unacceptable drug-related adverse effects. The investigators reported a median overall survival of 6.8 months. After treatment with ensituximab, 21% of patients demonstrated stable disease.

Common treatment-related adverse events included fatigue (38%), anemia (30%), nausea (15%), vomiting (11%), increased bilirubin (9%), constipation (8%), decreased appetite (6%), and diarrhea (6%). Moreover, 4 of the 63 patients experienced severe adverse effects, including hypoxia, as a result of treatment with ensituximab. However, despite these adverse events, all patients completed the entire treatment regimen.

“A previously conducted phase I trial demonstrated predictable pharmacokinetic profile and elevation of IL-6 and IL-8 posttreatment,” the authors commented. “These findings provide a supporting rationale for investigating combination therapies using ensituximab with IL-15 or other agents such as chemotherapy, to enhance efficacy in this patient population.”

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.